Biospace: Errant Escalates Complaints to Lawsuit Over bluebird bio’s Gene Therapy

The ongoing battle between bluebird bio and tiny Errant Gene Therapeutics has escalated into a full-blown patent lawsuit, with Chicago-based Errant alleging that bluebird’s LentiGlobin and Zynteglo gene therapies infringe on patents for recombinant vectors they own.

View the rest of the article here

View the PDF